Parexel Exec Says Non-COVID-19 Drug Discovery Back With A Bang
Block Chain Use Could Aid Trials
Clinical trial initiations in cell and gene therapies and immuno-oncology are seeing a spike as the COVID-19 experience has shown the benefits of beginning research early, Parexel’s executive vice president says. In an interview with Scrip, Sanjay Vyas discusses a range of topics from diversity to the advantages of block chain and growth in China
